Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


US FDA Approval Of Valeant’s Siliq Comes With REMS, Boxed Warning

Executive Summary

Measures are aimed at mitigating risk of suicidal ideation and behavior with the psoriasis drug, but company will not have to conduct a postmarketing registry to evaluate this risk.


Related Content

Valeant On Track With Debt-Reduction Goals, But Will It Be Enough?
Siliq Probably Isn't The Light At The End Of Valeant's Tunnel
Novel US FDA Approvals Could Rebound In 2017: 40+ Candidates Already Under Review
Keeping Track: US FDA Approves Siliq, Accepts Mylan/Biocon Pegfilgrastim Biosimilar
FDA's NDA And BLA Approvals: Siliq
Where’s The Suffix? Valeant’s Siliq Approved Without Four-Letter Identifier
Post-Marketing Registry, Suicidality Warning Could Be Paradox For Siliq
Valeant's Siliq Clears FDA Panel But Faces Prospect Of Post-Marketing Registry


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts